

Lifeline Drugs & Pharma Limited

Regd Office : 17, 3rd Floor, Zaveri Bhavan, 85/87, Old Hanuman Lane, Kalbadevi Road, Mumbai-400 002

(₹ In Lacs)

Unaudited Financial Results for the Quarter & Half Year ended September 30, 2013

Sr. No.	Particulars	3 Months ended 30.09.2013	Preceding 3 Months ended 30.06.2013	Corresponding 3 Months ended 30.09.2012	Corresponding 6 Months ended 30.09.2013	Corresponding 6 Months ended 30.09.2012	Year to date figures as on 31.03.2013
		Un-Audited			Un-Audited		Audited
1	Income from Operations						
	a) Net Sales/Income from Operations	325.72	958.24	-	1,283.96	-	-
	b) Other Operating Income	-	-	-	-	-	-
	Total Income from Operations (Net)	325.72	958.24	-	1,283.96	-	-
2	Expenditure						
	(a) Cost of Material Consumed	-	-	-	-	-	-
	(b) Purchases of Stock-in-trade	320.07	944.63	-	1,264.70	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(d) Employees Benefit Expenses	1.48	1.95	1.02	3.43	1.50	3.75
	(e) Depreciation & Amortization Expenses	-	-	-	-	-	-
	(f) Exchange & Depository Expenses	-	-	1.98	-	1.98	-
	(g) Other Expenditure	2.42	1.50	2.24	3.92	3.83	4.51
	Total Expenses	323.97	948.08	5.24	1,272.05	7.31	8.26
3	Profit/(Loss) from Operations before other income, finance cost and exceptional Expenses (1-2)	1.75	10.16	(5.24)	11.91	(7.31)	(8.26)
4	Other Income/(Loss)	9.84	-	10.12	9.84	12.90	28.64
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	11.59	10.16	4.88	21.75	5.59	20.38
6	Finance Costs	-	-	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3+4)	11.59	10.16	4.88	21.75	5.59	20.38
8	Exceptional Items	-	-	-	-	-	-
9	Profit(+)/Loss(-) from ordinary activities before Tax (7-8)	11.59	10.16	4.88	21.75	5.59	20.38
10	Tax Expenses	-	-	-	-	-	6.30
11	Net Profit (+)/Loss(-) from ordinary activities after tax (9-10)	11.59	10.16	4.88	21.75	5.59	14.09
12	Extra Ordinary Items (Net of Tax Expense of Rs. Lac)	-	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11-12)	11.59	10.16	4.88	21.75	5.59	14.09
14	Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15)	11.59	10.16	4.88	21.75	5.59	14.09
15	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	362.40	307.40	120.00	362.40	120.00	307.40
16	Reserves excluding revaluation Reserves as per last Balance Sheet	-	-	-	-	-	968.27
17	Earning Per Share (before extra-ordinary items) of Rs. 10/- each (not annualized)						
(i)	a) Basic	0.32	0.33	0.41	0.60	0.47	0.46
	b) Diluted	0.32	0.33	0.41	0.69	0.47	0.46
17	Earning Per Share (after extra-ordinary items) of Rs. 10/- each (not annualized)						
(ii)	a) Basic	0.32	0.33	0.41	0.60	0.47	0.46
	b) Diluted	0.32	0.33	0.41	0.69	0.47	0.46
A	PARTICULARS OF SHAREHOLDING						
	Public Shareholding						
	- Number of Shares	3,621,500	3,071,500	1,197,500	3,621,500	1,197,500	3,071,500
	- Percentage of Share Holding	99.93	99.92	99.79	99.93	99.79	99.92
18	Promoter and Promoter Group Shareholding						
a)	Pledged/Encumbered	-	-	-	-	-	-
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-	-	-
b)	None-Encumbered						
	- Number of Shares	2,500	2,500	2,500	2,500	2,500	2,500
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the Company)	0.07	0.08	0.21	0.07	0.21	0.08
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the Quarter	Nil	Disposed during the Quarter				Nil
	Received during the Quarter	Nil	Remaining Unresolved at the end of Quarter				Nil

Notes :

1. Segmental Report for the Quarter as per AS-17 of ICAI is not applicable for the Quarter.
2. Above results were reviewed by Audit Committee taken on record in Board Meeting held on 12th November, 2013.
3. Provision for Taxation will be made at the end of the Financial Year.
4. The Statutory Auditors of the Company have carried out "Limited Review" of the above Financial Results.

For Lifeline Drugs & Pharma Limited

S/d-

Alok Behera
Managing Director

Place : Mumbai

Date : 12th November 2013

Lifeline Drugs & Pharma Limited
Statement of Assets & Liabilities

Rs. in Lacs

Particulars		For the Half Year Ended	
		30th Sept 2013	30th Sept 2012
		Un-Audited	Un-Audited
A	EQUITY & LIABILITIES		
1	Shareholders' Fund		
	(a) Share Capital	362.40	120.00
	(b) Reserves and Surplus	1,721.52	239.71
	(c) Money Received against Share Warrants	-	-
	Sub-Total – Share Holders Fund	2,083.92	359.71
2	Share Capital Money (Pending Allotment)	-	41.85
3	Minority Interest*	-	-
4	Non Current Liabilities		
	(a) Long Term Borrowings	-	-
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	Sub-Total – Long Term Liabilities	-	-
5	Current Liabilities		
	(a) Short Term Borrowings	-	-
	(b) Trade Payables	322.12	53.65
	(c) Other Current Liabilities	-	53.45
	(d) Short Term Provisions	21.78	14.91
	Sub-Total – Current Liabilities	343.90	122.01
	TOTAL EQUITY & LIABILITIES	2,427.82	523.57
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets	-	-
	(b) Goodwill on Consolidation*	-	-
	(c) Non-Current Investments	-	-
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long Term Loans & Advances	-	-
	(f) Other Non-Current Assets	-	-
	Sub-Total – Non Current Assets	-	-
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	613.08	2.08
	(c) Trade Receivables	512.29	157.89
	(d) Cash & Cash Equivalents	13.81	303.70
	(e) Short Term Loans & Advances	1,288.64	46.25
	(f) Other Current Assets	-	13.65
	Sub-Total – Current Assets	2,427.82	523.57
	TOTAL – ASSETS	2,427.82	523.57